This supports earlier observations that activation of the Akt/mTOR pathway contributes to cisplatin resistance in ovarian cancer cells.45 Resistance to cisplatin, the key drug in treatment of HGSOC, may explain the worsened outcomes associated with Y163C. Here, MTOR is linked to ovarian cancer.